title: The disaccharide moiety of bleomycin facilitates uptake by cancer cells.
abstract: The disaccharide moiety is responsible for the tumor cell targeting properties of bleomycin (BLM). While the aglycon (deglycobleomycin) mediates DNA cleavage in much the same fashion as bleomycin, it exhibits diminished cytotoxicity in comparison to BLM. These findings suggested that BLM might be modular in nature, composed of tumor-seeking and tumoricidal domains. To explore this possibility, BLM analogues were prepared in which the disaccharide moiety was attached to deglycobleomycin at novel positions, namely, via the threonine moiety or C-terminal substituent. The analogues were compared with BLM and deglycoBLM for DNA cleavage, cancer cell uptake, and cytotoxic activity. BLM is more potent than deglycoBLM in supercoiled plasmid DNA relaxation, while the analogue having the disaccharide on threonine was less active than deglycoBLM and the analogue containing the C-terminal disaccharide was slightly more potent. While having unexceptional DNA cleavage potencies, both glycosylated analogues were more cytotoxic to cultured DU145 prostate cancer cells than deglycoBLM. Dye-labeled conjugates of the cytotoxic BLM aglycons were used in imaging experiments to determine the extent of cell uptake. The rank order of internalization efficiencies was the same as their order of cytotoxicities toward DU145 cells. These findings establish a role for the BLM disaccharide in tumor targeting/uptake and suggest that the disaccharide moiety may be capable of delivering other cytotoxins to cancer cells. While the mechanism responsible for uptake of the BLM disaccharide selectively by tumor cells has not yet been established, data are presented which suggest that the metabolic shift to glycolysis in cancer cells may provide the vehicle for selective internalization.
authors.affiliation: Department of Chemistry, University of Virginia , Charlottesville, Virginia 22904, United States.
authors.forename: Benjamin R
authors.initials: BR
authors.lastname: Schroeder
authors.forename: M Imran
authors.initials: MI
authors.lastname: Ghare
authors.forename: Chandrabali
authors.initials: C
authors.lastname: Bhattacharya
authors.forename: Rakesh
authors.initials: R
authors.lastname: Paul
authors.forename: Zhiqiang
authors.initials: Z
authors.lastname: Yu
authors.forename: Paul A
authors.initials: PA
authors.lastname: Zaleski
authors.forename: Trevor C
authors.initials: TC
authors.lastname: Bozeman
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Rishel
authors.forename: Sidney M
authors.initials: SM
authors.lastname: Hecht
mesh_terms: D001761:Bleomycin / Q000737:chemistry* / Q000378:metabolism* / Q000494:pharmacology; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D053837:DNA Cleavage / Q000187:drug effects; D004187:Disaccharides / Q000737:chemistry*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008297:Male; D015394:Molecular Structure; D011471:Prostatic Neoplasms / Q000378:metabolism* / Q000473:pathology*; D013329:Structure-Activity Relationship
chemical_list: D004187:Disaccharides; D001761:Bleomycin